Anyplex™II MTB/XDR Detection simultaneously detects and identifies Mycobacterium tuberculosis (MTB) and 13 mutations associated with XDR-TB. Based on Seegene’s proprietary DPO™ and TOCE™ technologies, this assay performs on multiplex real-time PCR instruments and provide prompt diagnosis and appropriate treatment guideline for tuberculosis control.
Simultaneous detection of Mycobacterium tuberculosis and 13 mutations associated with XDR-TB
WTC(Wild-type Control) and Internal Control (IC) for assay validity
Reagent for DNA Detection is provided, purchase of DNA extraction kit is unnecessary
Wide range of applicable specimens
Fast treatment decision by simultaneous screening and subtyping
Detection and identification of mutations associated antibiotic resistance for appropriate infection control
Multiplex real-time PCR with high sensitivity and specificity by utilization of DPO™ and TOCE™ technologies
Utilization of the UDG system to prevent carry-over contamination
Automated data interpretation and LIS interlocking with Seegene Viewer
These results indicate the detection of MTB infection in the FAM channel, and the Fluoroquinolone-resistance mutation in the HEX channel and the Injectable drug-resistance-R2* mutation in the Cal Red 610 channel.
(* High level Kanamycin, Amikacin, Capreomycin resistance)
 The WTC is designed to be exhibited the same result pattern with drug-susceptible M. tuberculosis sample. The WTC reaction should be always performed in each testing run, and the drug-resistant result of unknown samples is analyzed on the basis of the result of WTC.
 Extensively Drug Resistance